We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.81B
1-Year Est. Return 192.15%
This Fund
S&P 500
This Quarter Est. Return
+7.48%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$775M
AUM Growth
+$123M
Cap. Flow
+$131M
Cap. Flow %
16.88%
Top 10 Hldgs %
77.34%
Holding
39
New
8
Increased
12
Reduced
14
Closed
4

Top Buys

Rank Stock Value
1
TSVT
2seventy bio
TSVT
+$42.7M
2
TVTX icon
Travere Therapeutics
TVTX
+$24.3M
3
PCVX icon
Vaxcyte
PCVX
+$21.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$16M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$16M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$27.8M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$25.8M
3
VRDN icon
Viridian Therapeutics
VRDN
+$15.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.5M
5
CLDX icon
Celldex Therapeutics
CLDX
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Miscellaneous 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47.3B
$162M 20.92%
2,918,237
+315,030
+12% +$15.1M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$119M 15.42%
1,094,620
-5,380
-0.5% -$595K
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.84B
$67.7M 8.74%
3,205,986
+644,799
+25% +$16M
CLDX icon
4
Celldex Therapeutics
CLDX
$3.12B
$50.7M 6.55%
1,409,451
-195,939
-12% -$8.45M
PCVX icon
5
Vaxcyte
PCVX
$9.1B
$45.6M 5.89%
1,216,784
+513,343
+73% +$21.8M
TSVT
6
DELISTED
2seventy bio
TSVT
$38.1M 4.92%
+3,738,972
New +$42.7M
TVTX icon
7
Travere Therapeutics
TVTX
$6.15B
$35.2M 4.54%
1,563,595
+1,145,496
+274% +$24.3M
PTGX icon
8
Protagonist Therapeutics
PTGX
$9.43B
$31.6M 4.08%
1,375,000
+854,078
+164% +$14.3M
VERA icon
9
Vera Therapeutics
VERA
$2.59B
$26.2M 3.38%
3,372,428
+1,963,330
+139% +$15.2M
BNR
10
Burning Rock Biotech
BNR
$126M
$22.5M 2.91%
802,063
+62,905
+9% +$1.88M
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$20.2M 2.61%
+100,000
New +$16M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.6M 2.4%
499,853
+308,695
+161% +$13.9M
AMRN
13
Amarin Corp
AMRN
$288M
$18M 2.32%
600,000
+117,888
+24% +$4.13M
GSK icon
14
GSK
GSK
$100B
$17.7M 2.29%
498,329
-3,314
-0.7% -$116K
WVE icon
15
Wave Life Sciences
WVE
$958M
$16.5M 2.13%
3,807,876
+2,569,694
+208% +$11.8M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.6B
$13.8M 1.79%
543,603
-491,094
-47% -$15.7M
LQDA icon
17
Liquidia Corp
LQDA
$6.15B
$11.3M 1.46%
1,642,244
-110,597
-6% -$755K
IOVA icon
18
Iovance Biotherapeutics
IOVA
$3.98B
$11M 1.42%
+1,800,000
New +$12.4M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.55B
$8.34M 1.08%
+1,000,000
New +$9.63M
ALLO icon
20
Allogene Therapeutics
ALLO
$681M
$7.39M 0.95%
1,495,981
+1,099,603
+277% +$7.05M
OLMA icon
21
Olema Pharmaceuticals
OLMA
$941M
$6.98M 0.9%
2,011,853
-13,381
-0.7% -$54.6K
MCRB icon
22
Seres Therapeutics
MCRB
$57.5M
$4.36M 0.56%
38,446
-387
-1% -$41.9K
COGT icon
23
Cogent Biosciences
COGT
$6.03B
$4.32M 0.56%
399,974
-394,075
-50% -$5.04M
STRO icon
24
Sutro Biopharma
STRO
$333M
$4.17M 0.54%
90,184
+49,730
+123% +$3.16M
CNTA
25
DELISTED
Centessa Pharmaceuticals
CNTA
$2.81M 0.36%
729,077
-4,849
-0.7% -$17.7K
1
2

Similar funds

AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
SFG
Sage Financial Group W. Conshohocken, Pennsylvania $1.81B AUM 22.3% 1-Year Est. Return
GA
Greenspring Advisors Towson, Maryland $1.8B AUM 22.29% 1-Year Est. Return
CCS
Concentric Capital Strategies Stamford, Connecticut $1.8B AUM 51.77% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.8B AUM 22.23% 1-Year Est. Return

Kynam Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Kynam Capital Management held 39 positions worth $775M, up 19% from $652M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Kynam Capital Management deployed $131M of net new capital in Q1 2023, opening 8 new positions and adding to 12 existing holdings. Its largest new stake was 2seventy bio: 3,738,972 shares worth $38.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $15.7M trimmed.

  • Kynam Capital Management's largest Q1 2023 buy was 2seventy bio: 3,738,972 shares worth $38.1M.
  • Kynam Capital Management added most to Travere Therapeutics in Q1 2023, an estimated $24.3M increase.
  • Kynam Capital Management's biggest Q1 2023 reduction was Viridian Therapeutics, cutting an estimated $15.7M.
  • Kynam Capital Management fully exited United Therapeutics in Q1 2023, selling an estimated $27.8M.
  • Kynam Capital Management's ten largest holdings make up 77% of its $775M portfolio in Q1 2023.
  • Kynam Capital Management opened 8 new positions and closed 4 in Q1 2023.
  • Kynam Capital Management's portfolio value rose 19% quarter-over-quarter to $775M.

Based on Kynam Capital Management's 13F filing for Q1 2023, filed 15 May 2023.